102 related articles for article (PubMed ID: 8468713)
1. Suramin: here to stay!?
Scher HI
J Natl Cancer Inst; 1993 Apr; 85(8):594-7. PubMed ID: 8468713
[No Abstract] [Full Text] [Related]
2. Suramin administration is associated with a decrease in serum calcium levels.
Walther MM; Rehak NN; Venzon D; Myers CE; Linehan WM; Figg WD
World J Urol; 2000 Dec; 18(6):388-91. PubMed ID: 11204256
[TBL] [Abstract][Full Text] [Related]
3. A Phase II trial of suramin monthly x 3 for hormone-refractory prostate carcinoma.
Vogelzang NJ; Karrison T; Stadler WM; Garcia J; Cohn H; Kugler J; Troeger T; Giannone L; Arrieta R; Ratain MJ; Vokes EE
Cancer; 2004 Jan; 100(1):65-71. PubMed ID: 14692025
[TBL] [Abstract][Full Text] [Related]
4. Suramin for prostatic cancer: a phase I/II study in advanced extensively pretreated disease.
Van Oosterom AT; De Smedt EA; Denis LJ; de Bruijn EA; Mahler C
Eur J Cancer; 1990 Apr; 26(4):422. PubMed ID: 2141506
[No Abstract] [Full Text] [Related]
5. Other chemotherapy regimens including mitoxantrone and suramin.
Siu LL; Moore MJ
Semin Urol Oncol; 1997 Feb; 15(1):20-7. PubMed ID: 9050136
[TBL] [Abstract][Full Text] [Related]
6. Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone.
Small EJ; Meyer M; Marshall ME; Reyno LM; Meyers FJ; Natale RB; Lenehan PF; Chen L; Slichenmyer WJ; Eisenberger M
J Clin Oncol; 2000 Apr; 18(7):1440-50. PubMed ID: 10735891
[TBL] [Abstract][Full Text] [Related]
7. Timing of the administration of suramin treatment after muscle injury.
Nozaki M; Ota S; Terada S; Li Y; Uehara K; Gharaibeh B; Fu FH; Huard J
Muscle Nerve; 2012 Jul; 46(1):70-9. PubMed ID: 22644812
[TBL] [Abstract][Full Text] [Related]
8. Suramin and prostate cancer: where do we go from here?
Clark JW; Chabner BA
J Clin Oncol; 1995 Sep; 13(9):2155-7. PubMed ID: 7666073
[No Abstract] [Full Text] [Related]
9. Suramin, an active drug for prostate cancer: interim observations in a phase I trial.
Eisenberger MA; Reyno LM; Jodrell DI; Sinibaldi VJ; Tkaczuk KH; Sridhara R; Zuhowski EG; Lowitt MH; Jacobs SC; Egorin MJ
J Natl Cancer Inst; 1993 Apr; 85(8):611-21. PubMed ID: 8468719
[TBL] [Abstract][Full Text] [Related]
10. Androgen deprivation and four courses of fixed-schedule suramin treatment in patients with newly diagnosed metastatic prostate cancer: A Southwest Oncology Group Study.
Hussain M; Fisher EI; Petrylak DP; O'Connor J; Wood DP; Small EJ; Eisenberger MA; Crawford ED
J Clin Oncol; 2000 Mar; 18(5):1043-9. PubMed ID: 10694555
[TBL] [Abstract][Full Text] [Related]
11. Suramin, an active nonhormonal cytotoxic drug for treatment of prostate cancer: compelling reasons for testing in patients with hormone-refractory breast cancer.
Eisenberger MA; Fontana JA
J Natl Cancer Inst; 1992 Jan; 84(1):3-5. PubMed ID: 1738171
[No Abstract] [Full Text] [Related]
12. Suramin as adjuvant therapy with radical prostatectomy.
Saffrin R; Chou P; Ray V; Shaw M; Rubenstein M; Guinan P
Prostate; 1996 May; 28(5):325-7. PubMed ID: 8610060
[TBL] [Abstract][Full Text] [Related]
13. A pilot trial of suramin in metastatic breast cancer to assess antiangiogenic activity in individual patients.
Gradishar WJ; Soff G; Liu J; Cisneros A; French S; Rademaker A; Benson AB; Bouck N
Oncology; 2000 May; 58(4):324-33. PubMed ID: 10838499
[TBL] [Abstract][Full Text] [Related]
14. Ocular symptoms and signs associated with suramin sodium treatment for metastatic cancer of the prostate.
Hemady RK; Sinibaldi VJ; Eisenberger MA
Am J Ophthalmol; 1996 Mar; 121(3):291-6. PubMed ID: 8597272
[TBL] [Abstract][Full Text] [Related]
15. Feasibility and pharmacokinetics of intraperitoneal suramin in advanced malignancy.
Westermann AM; Dubbelman R; Baars JP; Moolenaar WH; Beijnen JH; Rodenhuis S
Cancer Chemother Pharmacol; 2000; 46(1):57-62. PubMed ID: 10912579
[TBL] [Abstract][Full Text] [Related]
16. Determination of suramin in clinical samples using HPLC.
Brandsteterová E; Chovancová V; Koza I; Mardiak J; Hal'ko J
Neoplasma; 1991; 38(4):425-32. PubMed ID: 1922574
[TBL] [Abstract][Full Text] [Related]
17. Suramin: development of a population pharmacokinetic model and its use with intermittent short infusions to control plasma drug concentration in patients with prostate cancer.
Jodrell DI; Reyno LM; Sridhara R; Eisenberger MA; Tkaczuk KH; Zuhowski EG; Sinibaldi VJ; Novak MJ; Egorin MJ
J Clin Oncol; 1994 Jan; 12(1):166-75. PubMed ID: 8270974
[TBL] [Abstract][Full Text] [Related]
18. Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480.
Small EJ; Halabi S; Ratain MJ; Rosner G; Stadler W; Palchak D; Marshall E; Rago R; Hars V; Wilding G; Petrylak D; Vogelzang NJ
J Clin Oncol; 2002 Aug; 20(16):3369-75. PubMed ID: 12177096
[TBL] [Abstract][Full Text] [Related]
19. New molecules and treatment modulation in advanced prostatic cancer.
Mahler C; Verhelst J; Denis L
Acta Urol Belg; 1996 May; 64(2):95-8. PubMed ID: 8701825
[No Abstract] [Full Text] [Related]
20. Suramin for breast and prostate cancer: a pilot study of intermittent short infusions without adaptive control.
Woll PJ; Ranson M; Margison J; Thomson Y; van der Water L; George N; Howell A
Ann Oncol; 1994 Sep; 5(7):597-600. PubMed ID: 7993834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
